Synageva raises $211 million in follow-on

Synageva BioPharma Corp. (NASDAQ:GEVA) raised $211 million on Thursday through the sale of 2 million shares at $105.75 in the largest follow-on so far this year. The company proposed the offering late Tuesday, when its share price was $103.99. Goldman Sachs; JPMorgan; Morgan Stanley; Cowen; Canaccord; Baird; and Nomura Securities are underwriters.

Synageva's sebelipase alfa (formerly SBC-102) is in the Phase III ARISE trial for late onset lysosomal acid lipase (LAL) deficiency (cholesteryl ester storage disease), with data expected next half. By 1Q15, Synageva plans to submit a BLA to FDA and an MAA to EMA for the recombinant human LAL enzyme replacement therapy (ERT) to treat LAL deficiency. ...